Veru targets Q1 2027 PLATEAU interim analysis after enrolling 239 patients (NASDAQ:VERU)
Veru (VERU) Q3 FY2026 earnings call: PLATEAU Phase IIb enrollment, Q1 2027 interim catalyst, Novo Wegovy deal, patents to 2044, cash runwayâread now.
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
Veru (VERU) Q3 FY2026 earnings call: PLATEAU Phase IIb enrollment, Q1 2027 interim catalyst, Novo Wegovy deal, patents to 2044, cash runwayâread now.
Veru targets Q1 2027 PLATEAU interim analysis after enrolling 239 patients (NASDAQ:VERU) | Seeking Alpha
Earnings Call Insights: Veru Inc. (VERU) Q3 fiscal 2026
Management view
Dr. Mitchell Steiner said Veru is focused on two small molecules, with near-term emphasis on enobosarm in obesity: enobosarm is being developed âas a next-generation drug that when combined with a GLP-1 receptor
Seeking Alpha's Disclaimer:
This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Quick Insights
What are the key catalysts for Veruâs near-term value in obesity drug development?
The fully enrolled Phase IIb PLATEAU trial with interim (32-week) data expected soon, partnerships such as the Novo Nordisk Wegovy agreement, and the issuance of key IP/patents.
How do Veruâs financial health and funding runway impact the risk profile?
Veru has negative cash flow, is not profitable, but reports sufficient cash to fund operations beyond the PLATEAU trialâs interim readout according to current plans.
What is the strategic significance of Veruâs intellectual property and Novo Nordisk agreement for future commercialization?
Veru gained a broad patent allowance for enobosarm with all weight-loss drugs, has a patent extending to at least 2044, and secured a Novo Nordisk Wegovy supply agreement with right of first negotiation, strengthening IP and commercial positioning.
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
Solana Company Stakes 500K SOL on Tokyo Cluster, Validator Rewards Expected by Q3 2026
A Solana infrastructure firm has pledged 500,000 SOL to support its Tokyo cluster, with first validator rewards projected for Q3 2026, signaling confidence in network decentralization and Asian expansion.
Barfresh outlines $23M-$26M FY2026 revenue outlook while targeting partial commissioning of Defiance plant by end of 2026 (NASDAQ:BRFH)
Barfresh (BRFH) Q2 2026 earnings call recap: Arps-driven revenue growth, production ramp issues, and revised FY2026 guidance.
Sidus Fortis VPX Commercial Launch in 2027 Backed by $158.5M Funding
Sidus Space announces the commercial availability of its Fortis VPX edge computing module by early 2027, supported by $158.5M raised in Q2 2025. Learn about its technology advantages, market outlook, and financial health.
TOMI Reaffirms 2026 Revenue Guidance of at Least $12M, Sets $10M Funding Goal for Carbonium Core Merger
TOMI Environmental Solutions reaffirms its 2026 revenue guidance of at least $12 million and advances its merger with Carbonium Core, targeting $10 million in funding. This article analyzes the strategic implications, industry context, and potential risks.
